Table 1.

Generalised properties of anti-influenza viral antibodies.

Monoclonal antibodies	Polyclonal antibodies
High cost	Low cost
Hybridoma-derived	Animal-derived
Low scale-up	High scale-up
Single epitope specificities	Multiple epitope specificities
Defined purity	Undefined purity
Broadly neutralizing	Broadly neutralizing
Selection of resistant mutants	Less selection of resistant mutants
Initial efficacy	Long-term efficacy